HLA-A24
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| major histocompatibility complex (human), class I, A24
| ||
| Alleles | A*2402 A*2403 | |
| Structure (See HLA-A) | ||
| Identifiers | 2402 2403
| |
| Symbol(s) | HLA-A | |
| EBI-HLA | A*2402 | |
| Shared data | ||
| Locus | chr.6 6p21.31 | |
HLA-A24 (A24) is an HLA-A serotype. The serotype identifies the more common HLA-A*24 gene products. A24 is a split antigen that is also recognized by the A9 broad antigen type. This broad antigen also recognizes the similar A23 types. A24 is common in Austronesia. A*2402 has one of the highest A allele frequencies for a number of peoples, including Papua New Guineans, Indigeonous Taiwanese (Eastern Tribals), Yupik and Greenland Eskimos. It is common over much of Southeastern Asia. In eurasia it is least common in Ireland, and it is relatively uncommon in Africa except North Africa and Kenya.
Serotype
| A*24 | A24 | A9 | Sample |
| allele | % | % | size (N) |
| 2402 | 97 | 3098 | |
| 2402 | 55 | 4 | 282 |
There are over 90 known A*24 alleles, 69 code for different isoforms and 7 are nulls.
Disease Associations
By serotype
A24 has a secondary risk factor for myasthenia gravis,,[2] Buerger's disease[3]
By allele
A*2402 is a secondary risk factor,[4] alters type 1 diabetes risk,[5][6] and allele associated with thyomoma induced myasthenia gravis.
A24-B Haplotypes
| freq | Rank in | |||
| ref. | Population | (%) | Pop. | |
| [7] | Java (Indonesia) | 8.0 | 1 | 4 |
| [7] | S. Amer. Native | 6.3 | 1 | 3 |
| [7] | N. Amer. Native | 5.4 | 1 | 5 |
| [7] | Mexican | 4.7 | 1 | |
| [7] | Inuit | 4.2 | 1 | |
| [7] | Brazilian | 3.8 | 1 | |
| [7] | Austria | 3.5 | 1 | |
| [7] | Portuguese | 3.1 | 1 | 3 |
| [7] | Yakut | 2.9 | 1 | |
| [7] | Mongolian | 2.7 | 1 | |
| [7] | Timor | 2.5 | 1 | 5 |
| [7] | Bharghavas (India) | 2.4 | 1 | |
| [7] | Greek | 2.3 | 1 | |
| [7] | Italian | 2.2 | 1 | |
| [7] | Mongolian | 1.9 | 1 | |
| [7] | Vietnamese | 1.8 | 1 | |
| [7] | Japanese | 1.6 | 2 | |
| [7] | French | 1.2 | 2 | |
| 1 Cw4. 2 Cw9. | ||||
A24-Cw7-B39 A24-Cw10-B60 A24-Cw10-B61 A24-B48
A24-Cw4-B35
This particular haplotype is common across a fairly wide region, possibly the most widely spread A-Cw-B haplotype in humans. Cw4-B35 has a node within the region once referred to as Thracia/Dacia.
A24-Cw*14-B51
| freq | ||
| ref. | Population | (%) |
| [7] | Korean | 3.5 |
| [7] | Iyers | 3.4 |
| [7] | Mongolian | 2.9 |
| [7] | Japanese | 2.6 |
| [7] | Romanian | 2.2 |
| [7] | Greek | 2.1 |
| [7] | Hungarian | 2.0 |
| [7] | Italian | 0.6 |
References
- ↑ derived from IMGT/HLA
- ↑ Machens A, Löliger C, Pichlmeier U, Emskötter T, Busch C, Izbicki J (1999). "Correlation of thymic pathology with HLA in myasthenia gravis.". Clin Immunol 91 (3): 296-301. PMID 10370374.
- ↑ Numano F, Sasazuki T, Koyama T, Shimokado K, Takeda Y, Nishimura Y, Mutoh M (1986). "HLA in Buerger's disease.". Exp Clin Immunogenet 3 (4): 195-200. PMID 3274054.
- ↑ de Juan M, Reta A, Belzunegui J, Figueroa M, Maruri N, Cuadrado E (2004). "HLA-A*2402 and a microsatellite (D6S248) are secondary independent susceptibility markers to ankylosing spondylitis in Basque patients.". Hum Immunol 65 (2): 175-80. PMID 14969772.
- ↑ Noble J, Valdes A, Bugawan T, Apple R, Thomson G, Erlich H (2002). "The HLA class I A locus affects susceptibility to type 1 diabetes.". Hum Immunol 63 (8): 657-64. PMID 12121673.
- ↑ Nakanishi K, Inoko H (2006). "Combination of HLA-A24, -DQA1*03, and -DR9 Contributes to Acute-Onset and Early Complete {beta}-Cell Destruction in Type 1 Diabetes: Longitudinal Study of Residual {beta}-Cell Function.". Diabetes 55 (6): 1862-8. PMID 16731854.
- ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 7.22 7.23 7.24 7.25 Sasazuki, Takehiko; Tsuji, Kimiyoshi; Aizawa, Miki (1992). HLA 1991: proceedings of the eleventh International Histocompatibility Workshop and Conference, held in Yokohama, Japan, 6-13 November, 1991. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-262390-7.
HLA-A Serotypes |
|---|
| HLA-A - A1 - A2 - A3 - A9 (A23 - A24) - A10 (A25 - A26 - A34 - A43 - A66) - A11 - A19 (A29 - A30 - A31 - A32 - A33 - A74) - A28 (A68 - A69) - A36 - A80 |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
